AbbVie Beats on Q1 Earnings & Sales, Raises '25 EPS View

Core Viewpoint - AbbVie Inc. reported strong first-quarter 2025 results, with adjusted EPS and revenues exceeding estimates, driven by robust sales of key immunology drugs and newer products, despite a significant decline in Humira sales [1][2][18]. Financial Performance - Adjusted EPS for Q1 2025 was $2.46, beating the Zacks Consensus Estimate of$ 2.39 and the company's guidance of $2.34-$ 2.38, reflecting a 6.5% year-over-year increase [1]. - Revenues reached $13.34 billion, surpassing the Zacks Consensus Estimate of$ 12.91 billion and the company's forecast of $12.8 billion, with an 8.4% year-over-year increase on a reported basis and 9.8% on an operational basis [2]. Drug Performance - Immunology drugs drove revenue growth, with Rinvoq generating$ 1.72 billion (up 59.7%) and Skyrizi at $3.43 billion (up 72%), both exceeding estimates and company guidance [4][5]. - Humira sales declined 49.5% to$ 1.12 billion, with U.S. sales down 58% to $744 million, missing estimates due to loss of exclusivity [6][7]. - Neuroscience portfolio sales increased 17% to$ 2.28 billion, driven by Botox Therapeutic and migraine drugs, surpassing estimates [8]. - Oncology/hematology sales rose 7.5% to $1.63 billion, supported by Elahere and Venclexta, exceeding estimates [10]. Cost and Guidance - Adjusted SG&A expenses rose 8.2% to$ 3.28 billion, while adjusted R&D expenses increased 13.3% to $2.05 billion [16]. - AbbVie raised its full-year EPS guidance to$ 12.09- $12.29, up from$ 11.99-$12.19, reflecting stronger-than-expected sales from newer drugs [17]. Market Reaction - AbbVie shares rose over 5% in pre-market trading following the positive earnings report and guidance update, with a year-to-date gain of about 2% compared to the industry's 1% decline [19].